Skip to main content
    F

    Femasys Inc (FEMY)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ

    $1.74
    +0.17 (+11.22%)

    Market Cap: $13.06M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    57%(12/21)
    Avg Surprise
    +1.03%
    Streak
    5 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.60
    Range$-0.68 - $-0.53
    2 analysts
    EPS RevisionsNo revisions (7d)
    2
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-1.50+59.7%
    60d ago$-1.50+59.7%
    30d ago$-1.50+59.7%
    7d ago$-0.60-0.8%
    Current$-0.60
    Revenue Consensus
    $619500
    Range$439000 - $800000
    2 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.51
    Range$-0.94 - $-0.07
    2 analysts
    Revenue Consensus
    $-31670
    Range$-446170 - $382830
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.51---
    Sep 26EST
    		-$-0.60---
    Jun 26
    Reported Aug 14
    		$-1.33$-1.40+5.00%Beat+58.4%
    Mar 26
    Reported May 8
    		$-1.46$-1.80+18.89%Beat-534.8%
    Dec 25
    Reported Mar 31
    		$-0.20N/A+88.89%Beat+95.7%
    Sep 25
    Reported Nov 14
    		$-2.00$-2.60+23.08%Beat+58.3%
    Jun 25
    Reported Aug 8
    		$-3.20$-3.60+11.11%Beat+23.8%
    Mar 25
    Reported May 8
    		$-0.23$-0.19-21.05%Miss+93.2%
    Dec 24
    Reported Mar 27
    		$-4.60$-3.80-21.05%Miss-2321.1%
    Sep 24
    Reported Nov 12
    		$-4.80$-3.93-22.14%Miss+7.7%
    Jun 24
    Reported Aug 8
    		$-4.20$-3.47-21.04%Miss+4.5%
    Mar 24
    Reported May 9
    		$-3.40$-4.10+17.07%Beat-1260.0%
    Dec 23
    Reported Mar 28
    		$-0.19$-0.21+9.52%Beat+96.0%
    Sep 23
    Reported Nov 14
    		$-5.20$-5.00-4.00%Miss-4.0%
    Jun 23
    Reported Aug 10
    		$-4.40$-4.40+0.00%Beat+0.0%
    Mar 23
    Reported May 11
    		$-0.25$-0.26+3.85%Beat+94.8%
    Dec 22
    Reported Mar 30
    		$-4.80$-5.20+7.69%Beat-5900.0%
    Sep 22
    Reported Nov 10
    		$-5.00$-4.60-8.70%Miss-2531.6%
    Jun 22
    Reported Aug 10
    		$-4.40$-5.20+15.38%Beat-746.2%
    Mar 22
    Reported May 11
    		$-4.80$-4.20-14.29%Miss-1746.2%
    Dec 21
    Reported Mar 24
    		$-0.08N/A+68.00%Beat+90.0%
    Sep 21
    Reported Nov 10
    		$-0.19$-0.15-26.67%Miss+88.4%
    Jun 21
    Reported Aug 11
    		$-0.52$-0.25-108.00%Miss+66.6%
    Mar 21
    Reported Jun 21
    		$-0.26$0.00N/AMiss+88.7%
    Dec 20
    Reported Mar 17
    		$-0.80$0.00N/AMiss-
    Jun 20
    Reported Sep 30
    		$-1.64$0.00N/AMiss-
    Mar 20
    Reported Jun 29
    		$-1.55$0.00N/AMiss-
    Dec 19
    Reported Mar 30
    		$-2.30$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-0.35EV/EBITDAN/A
    Price/FCF-0.32xFCF Yield-310.31%
    Profitability
    Profit Margin0.00%Operating Margin-1527.00%
    ROE-425.00%ROIC-154.02%
    Financial Health
    Debt/Equity0.87xInterest Coverage-8.93x
    Current Ratio2.14xQuick Ratio0.55x
    Trading Statistics
    Beta-2.15Avg Volume97.62K
    52-Week High$22.2052-Week Low$1.47

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.90
    SMA 20$2.15
    SMA 50$2.50
    SMA 200$6.71
    EMA 10$1.89
    EMA 20$2.10
    EMA 50$2.61
    EMA 200$6.42

    MACD

    Line: -0.26Signal: -0.23Hist: -0.03

    ADX

    ADX: 32.2+DI: 10.0-DI: 28.2

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down96.0
    PSAR$1.99

    Bollinger Bands

    Upper Band$2.77
    Lower Band$1.52
    %B Position5830%(Upper)
    Band Width0.17

    RSI (14-Day)

    Neutral
    32.8

    Momentum Oscillators

    Stoch %K14.9
    Stoch %D10.2
    Williams %R-73.5
    ROC (10d)-17.4%
    Momentum-0.36
    CCI (20d)-128.1
    MFI (14d)19.5

    Volatility Measures

    ATR (14d)$0.23(13.4%)
    StdDev (20d)0.31
    Hist Vol90.9%(High)

    Volume Flow

    VWAP$1.67
    OBV307.1M
    AD Line160.0B
    CMF (20d)-0.320

    Volume Metrics

    Avg Vol (20d)100.1K
    Vol Ratio1.3x
    VWMA (20d)$2.04

    Pivot Points

    R3$2.00
    R2$1.88
    R1$1.72
    Pivot Point$1.59
    S1$1.43
    S2$1.31
    S3$1.15

    Advanced Oscillators

    TSI-36.95
    Ultimate Osc41.2
    KST-266.62

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$331,827$424,889$813,387$729,394$409,268$341,264$581,576$554,908$221,484$271,140$213,111$244,361
    Cost of Revenue$142,436$158,606$303,125$293,838$158,171$117,266$192,407$190,839$73,125$88,532$78,294$86,186
    Gross Profit$189,391$266,283$510,262$435,556$251,097$223,998$389,169$364,069$148,359$182,608$134,817$158,175
    Operating Expenses$5.26M$4.49M$5.13M$4.09M$4.10M$5.68M$5.11M$5.48M$4.63M$3.65M$4.58M$4.24M
    R&D$1.95M$1.31M$1.81M$1.38M$1.41M$2.97M$2.17M$2.30M$1.98M$1.77M$2.07M$2.07M
    SG&A$1.93M$1.78M$1.83M$1.48M$1.62M$1.72M$1.68M$1.53M$1.61M$1.50M$2.22M$1.97M
    Operating Income$-5,065,874$-4,223,533$-4,622,728$-3,653,768$-3,851,566$-5,460,607$-4,722,572$-5,118,440$-4,482,151$-3,462,642$-4,449,515$-4,081,264
    Interest Income$19,694$49,827$48,272$17,315$17,144$19,029$49,504$124,028$184,138$224,684$198,886$92,392
    Interest Expense$186,050$176,607$408,097$532,073$491,500$459,449$440,422$413,290$388,311$361,552$0$8,033
    Income Before Tax$-4,468,230$846,100$-3,944,820$-4,194,821$-4,585,922$-5,901,027$-5,113,490$-5,407,702$-4,686,324$-3,599,510$-4,406,116$-3,996,905
    Income Tax Expense$865$0$5,485$0$0$-4,188$10,194$1,158$-1,750$0$0$0
    Net Income$-4,469,095$846,100$-3,950,305$-4,194,821$-4,585,922$-5,896,839$-5,123,684$-5,408,860$-4,684,574$-3,599,510$-4,410,454$-3,996,905
    EBITDA$-3,918,418$1.35M$-4,201,408$-3,042,446$-3,506,756$-4,886,848$-4,166,645$-4,592,183$-3,982,455$-2,979,948$-4,099,408$-3,830,329
    EBIT$-4,301,874$972,880$-4,622,728$-3,680,063$-4,111,566$-5,460,607$-4,722,572$-5,118,440$-4,482,151$-3,462,642$-4,449,515$-4,081,264
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about FEMY

    News

    A fund manager reports a passive 468,750-share stake in Femasys (FEMY).

    Empery Asset Management, LP and Ryan M. Lane have reported a 5.6% passive stake in Femasys Inc. (FEMY), totaling 468,750 shares. This ownership figure is based on Femasys' 8,375,027 shares outstanding as of August 13...

    Stock Titan•10/15/26•Neutral

    Empery Asset Management Reports 5.6% Ownership Stake in Femasys Inc.

    Empery Asset Management, LP and Ryan M. Lane have reported a 5.6% beneficial ownership stake in Femasys Inc., totaling 468,750 shares of common stock. This disclosure was made in a Schedule 13G filing with the SEC...

    Kalkine Media•10/15/26•Neutral

    Form SCHEDULE 13G FEMASYS INC Filed by: Empery Asset Management, LP

    Empery Asset Management, LP and Ryan M. Lane have filed a Schedule 13G stating their beneficial ownership of 5.6% of Femasys Inc.'s common stock...

    StreetInsider•10/15/26•Neutral

    Femasys Doubles Enrolling Sites in FemBloc FINALE Pivotal Trial for Non-Surgical Permanent Birth Control

    Femasys Inc. has doubled the number of actively enrolling sites for its FemBloc FINALE Pivotal Trial to twelve across the United States. This expansion, enabled by August 2026 financing...

    Yahoo! Finance Canada•10/14/26•Bullish

    Femasys: Launch Is Funded. If The Sales Force Delivers, Then The Company Is In Tall Cotton

    Femasys (FEMY) is a commercial-stage medtech company focusing on in-office fertility and permanent birth control solutions for OB/GYNs. The company recently completed a $30M PIPE recapitalization...

    Seeking Alpha•10/14/26•Bullish

    FEMY Valuation and Fair Value

    P/E
    -0.3x
    P/FCF
    -0.3x
    P/B
    1.4x
    See GNG's fair value

    FEMY Profitability: Margins, ROIC and FCF

    Gross margin
    60.9%
    Operating margin
    -1527.0%
    Net margin
    0.0%
    ROIC
    -154.0%
    ROE
    -425.0%
    FCF margin
    -786.0%
    FCF yield
    -310.3%

    FEMY Competitors

    CompanyTicker
    Biofrontera IncBFRI
    GT Biopharma IncGTBP
    Tvardi Therapeutics, Inc.TVRD
    Anebulo Pharmaceuticals IncANEB
    Vyome Holdings, Inc.HIND
    Synlogic IncSYBX
    Citius Pharmaceuticals IncCTXR
    Tharimmune Inc.THAR

    Sector: Healthcare

    FEMY Analyst Ratings

    Consensus
    Strong Buy
    Analysts
    3
    Strong Buy
    2
    Buy
    1
    Hold
    0
    Sell
    0
    Strong Sell
    0

    FEMY Bull Case vs Bear Case

    Bear case

    • FEMY's quarterly revenue changed -18.9% year over year.

    FEMY Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    10.3%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.60
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    2 up, 0 down

    Frequently Asked Questions About FEMY

    Does FEMY pay dividends?

    Femasys Inc (FEMY) does not currently pay a regular dividend.

    What is FEMY's market cap?

    Femasys Inc (FEMY) has a market capitalization of $13.06M with a current stock price of $1.74.

    Related stocks

    Sector: Healthcare

    All stocks starting with F

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In